Italy's Menarini licenses Gan & Lee's obesity drug bofanglutide for Europe, paying €62M ($72M) upfront and up to €664M ($772M) in milestones.
September 4, 2026 06:44 AM EDT
DealsChinaGLP-1 drugs
Italy's Menarini gets into obesity with European rights to GLP-1 from China's Gan & Lee
Kyle LaHucik
Biotech Correspondent
PECHINO e FIRENZE Italia, 4 settembre 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals ('Gan & Lee'; codice azionario: 603087.SH)…
BrightGene's obesity shot BGM0504 posts strong Phase 3 data in China as it courts a Western partner ahead of a planned global…
In Novo Nordisk and Eli Lilly’s competition to launch their respective GLP-1 obesity pills in the United States, the Danish…
Companies have “tremendous concern” about the financial viability of these medications, the president and CEO of the Business…
Sciwind Biosciences has already licensed its GLP-1 obesity drug ecnoglutide twice over — to Pfizer and Verdiva Bio — but it is…
Swiss pharmaceutical firm Roche is investing billions in new obesity treatments in hopes of breaking into a highly competitive…
